SELLAS Life Sciences Group Inc (NASDAQ: SLS)’s stock price has gone rise by 1.33 in comparison to its previous close of 0.97, however, the company has experienced a 3.41% increase in its stock price over the last five trading days. globenewswire.com reported 2025-01-08 that – Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 – – SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 – – Approval of “tambiciclib” as Recommended International Nonproprietary Name for SLS009 – – Applied for Non-Dilutive Grant Funding to Expand SLS009 Development Into Frontline Setting in AML – – Developing SLS009 Pediatric Programs in Hematological and Potentially Other Malignancies – – Company to Host Corporate Update Webinar Today, January 8, 2025, at 9:00 am ET – NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a webinar at 9:00 am ET. “We believe that 2025 will be a pivotal year for SELLAS as we continue to advance our clinical stage portfolio of novel therapeutics for hematologic malignancies,” said Angelos Stergiou, MD, ScD h.c.
Is It Worth Investing in SELLAS Life Sciences Group Inc (NASDAQ: SLS) Right Now?
Moreover, the 36-month beta value for SLS is 2.38. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLS is 69.73M and currently, short sellers hold a 11.44% of that float. On January 17, 2025, SLS’s average trading volume was 1.18M shares.
SLS’s Market Performance
SLS stock saw an increase of 3.41% in the past week, with a monthly gain of 12.69% and a quarterly increase of -18.10%. The volatility ratio for the week is 7.28%, and the volatility levels for the last 30 days are 9.23% for SELLAS Life Sciences Group Inc (SLS). The simple moving average for the last 20 days is 1.66% for SLS’s stock, with a simple moving average of -20.05% for the last 200 days.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight.” The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
H.C. Wainwright gave a rating of “Buy” to SLS, setting the target price at $11 in the report published on April 02nd of the previous year.
SLS Trading at -8.90% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.86% of loss for the given period.
Volatility was left at 9.23%, however, over the last 30 days, the volatility rate increased by 7.28%, as shares surge +6.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.41% lower at present.
During the last 5 trading sessions, SLS rose by +3.41%, which changed the moving average for the period of 200-days by -8.15% in comparison to the 20-day moving average, which settled at $0.9667. In addition, SELLAS Life Sciences Group Inc saw -5.50% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLS
The total capital return value is set at -2.06. Equity return is now at value -535.10, with -186.64 for asset returns.
Based on SELLAS Life Sciences Group Inc (SLS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -57.42.
Currently, EBITDA for the company is 0.53 million with net debt to EBITDA at 1.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.26.
Conclusion
To wrap up, the performance of SELLAS Life Sciences Group Inc (SLS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
